ERBB2 and breast carcinoma: Interestingly, human KPL4 cells required depletion of both KLFs to impact BCL-XL abundance, possibly attributed to the activating phosphatidylinositide 3-kinase (PI3K) mutation present in this HER2-amplified, inflammatory breast cancer cell line (Figure 5b).47